HER2 expression across Brazilian gynecologic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective molecular epidemiology project that uses archived primary tumor paraffin blocks collected from adults diagnosed with gynecologic cancers between January 2020 and March 2025. Partner pathology labs in the OC Precision Medicine network will send slides to Locus Lab (São Paulo) for automated HER2 immunohistochemistry using Dako HercepTest and Roche Ventana 4B5. HER2 staining will be scored using multiple criteria (gastric, breast, and endometrial cancer scoring systems) to report rates of high expression (IHC 3+ by Dako/gastric criteria). The primary focus is prevalence in endometrial, ovarian, and cervical cancers, with secondary description for vulvar and vaginal cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>= 18 years at sample collection; - Diagnosis of cervical, endometrial, ovarian/peritoneum/uterine tube, vulvar, or vaginal cancers;
* Sufficient paraffin primary tumor tissue for biomarker testing in the OC Precision Medicine Pathology labs.
* Date of diagnosis of gynecological cancer must be from January 2020 to March 2025.
* Patients need to sign informed consent, or waiver of informed consent is granted.

Exclusion Criteria:

* Patients without sufficient paraffin tissue for the proposed biomarker testing.
* Patients whose diagnosis was performed in metastatic lesion.
* Patients with history of exposure to systemic anti-cancer therapies for the gynecological cancer diagnosis before surgery or excisional biopsy of gynecological cancer (information is available in the original histopathology request document stored in the LIMS).

Where it's running

• Research Site
  São Paulo, Brazil Recruiting

Study contacts

• Principal investigator: Angélica Nogueira Rodrigues — Oncoclínicas Precision Medicine
• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Vaginal Biomarkers for Early Gynaecological Cancers

  This study tests whether markers in vaginal secretions differ between people with and without gynaecological cancers to help detect cancers earlier and monitor treatment.

  Recruiting University Hospital Southampton NHS Foundation Trust · Southampton · NCT07622953

• Understanding the disease burden of hypophosphatasia in Chinese patients

  This study tests how hypophosphatasia affects people in China by collecting real-world data on symptoms, quality of life, and costs.

  Recruiting AstraZeneca · Beijing and 21 other locations · NCT07905287

• Real-world use of selumetinib for adult NF1 with inoperable plexiform neurofibromas

  This registry-following study tests how well and safely selumetinib works in adults with NF1 who have symptomatic, inoperable PN.

  Recruiting AstraZeneca · Beijing and 25 other locations · NCT07888517

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.